Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	266 people Data from 1 RCT	Dry mouth 6 weeks with olanzapine with placebo Absolute results not reported	RR 1.60 95% CI 0.47 to 5.41		Not significant
Systematic review	266 people Data from 1 RCT	Dizziness with olanzapine with placebo Absolute results not reported	RR 3.95 95% CI 0.96 to 16.31		Not significant
Systematic review	248 people 2 RCTs in this analysis	Needing anticholinergic medication 6 weeks with olanzapine with placebo Absolute results not reported	RR 0.90 95% CI 0.29 to 2.79		Not significant
Systematic review	266 people Data from 1 RCT	Akathisia 6 weeks with olanzapine with placebo Absolute results not reported	RR 4.12 95% CI 0.55 to 31.11		Not significant
Systematic review	266 people Data from 1 RCT	Tremor 6 weeks with olanzapine with placebo Absolute results not reported	RR 2.40 95% CI 0.30 to 19.19		Not significant
Systematic review	227 people 2 RCTs in this analysis	Mean difference in weight (units not given) 6 to 8 weeks with olanzapine with placebo Absolute results not reported	Mean difference +3.58 95% CI –1.18 to +8.34		Not significant
Systematic review	104 people Data from 1 RCT	Mean difference in weight (units not given) 3 to 12 months with olanzapine with placebo Absolute results not reported	Mean difference –0.52 95% CI –6.14 to +5.10		Not significant
RCT	107 adolescents	Mean change from baseline in prolactin (micrograms/L) 6 weeks +8.8 micrograms/L with olanzapine (mean daily dose 11.1 mg/day) –3.3 micrograms/L with placebo	P = 0.002	Effect size not calculated	placebo
RCT	107 adolescents	Mean change from baseline in weight (kg) 6 weeks 4.3 kg with olanzapine (mean daily dose 11.1 mg/day) 0.1 kg with placebo	P <0.001	Effect size not calculated	placebo
RCT	107 adolescents	Somnolence 24% with olanzapine (mean daily dose 11.1 mg/day) 3% with placebo Absolute numbers not reported	P = 0.006	Effect size not calculated	placebo
RCT	107 adolescents	Sedation 15% with olanzapine (mean daily dose 11.1 mg/day) 6% with placebo Absolute numbers not reported	P = 0.214		Not significant
RCT	107 adolescents	Mean change from baseline in extrapyramidal symptoms (Simpson-Angus Scale (SAS); Barnes Akathisia Scale (BAS); Involuntary Movement Scale (IMS) non-global total [questions 1–7]) 6 weeks with olanzapine (mean daily dose 11.1 mg/day) with placebo Absolute results not reported	SAS P = 0.260 BAS P = 0.747 IMS P = 0.897		Not significant
RCT	107 adolescents	Treatment with anticholinergic medication 4% with olanzapine (mean daily dose 11.1 mg/day) 6% with placebo Absolute numbers not reported	P = 0.661		Not significant